Effects of an endotoxin challenge on growth performance, carcass accretion rates, and serum hormone and metabolite concentrations in control pigs and those treated with recombinant porcine somatotropin.
Barrows were restrictively fed starting at 20 kg BW to determine the effects of endotoxin on growth performance of control and somatotropin-treated pigs. The following treatments were used: 1) daily i.m. vehicle injection until 55 kg BW; 2) daily i.m. injections of 100 micrograms of recombinant porcine somatotropin (pST)/kg BW, until 55 kg; 3) i.v. saline injections for 7 d consecutively starting at 60 kg BW; 4) i.v. injections of 1 microgram of bacterial lipopolysaccharide (LPS)/kg BW for 7 d starting at 60 kg BW; and 5) the combined LPS+pST treatment, with pST injections from 20 kg through the 7 d of LPS treatment. Pigs evaluated for LPS effects were fed to 60 kg anticipating a weight loss. Pigs were bled at 0800 and 1100 at 55 kg and on d 7 of LPS treatment. Rectal temperatures were taken on d 7. Treatment with pST increased ADG by 13 to 20% and improved feed:gain by 17 to 23% before LPS treatment. During the 7 d of LPS injections, ADG and feed:gain did not differ, although feed efficiency was impaired and variable. Rectal temperatures at 1100 were progressively increased: control < LPS < LPS-pST (P < .01). Protein accretion was improved 27% by pST treatment, and lipid accretion was decreased 45% before LPS. Lipid stores decreased (P < .01) after LPS treatment in the pST-treated pigs. Lipopolysaccharide treatment and(or) decreased feed intake reduced the hyperinsulinemia and hyperglycemia (P < .01) associated with pST treatment. These results indicate that LPS induced a simulated septicemia and that the effects were not negated by pST treatment. The observed hyperthermia was additive, possibly due to increased lean body mass induced by pST combined with the pyrogenic effect of LPS.
Evock-Clover
C M
CM
Growth Biology Laboratory, Livestock and Poultry Sciences Institute, USDA, Beltsville, MD 20705-2350, USA.
Myers
M J
MJ
Steele
N C
NC
D000818:Animals; D001786:Blood Glucose / Q000032:analysis / Q000378:metabolism*; D001823:Body Composition / Q000187:drug effects* / Q000502:physiology; D015992:Body Mass Index; D001831:Body Temperature / Q000187:drug effects / Q000502:physiology; D001835:Body Weight / Q000187:drug effects / Q000502:physiology; D004731:Endotoxins / Q000494:pharmacology*; D013006:Growth Hormone / Q000097:blood / Q000494:pharmacology*; D007273:Injections, Intramuscular / Q000662:veterinary; D007328:Insulin / Q000097:blood*; D007334:Insulin-Like Growth Factor I / Q000032:analysis / Q000378:metabolism*; D050356:Lipid Metabolism; D008070:Lipopolysaccharides / Q000494:pharmacology; D008297:Male; D008460:Meat / Q000592:standards*; D009584:Nitrogen / Q000097:blood; D011506:Proteins / Q000378:metabolism; D011994:Recombinant Proteins / Q000494:pharmacology; D013552:Swine / Q000097:blood* / Q000254:growth & development* / Q000378:metabolism; D014508:Urea / Q000097:blood
D001786:Blood Glucose; D004731:Endotoxins; D007328:Insulin; D008070:Lipopolysaccharides; D011506:Proteins; D011994:Recombinant Proteins; D007334:Insulin-Like Growth Factor I; D014508:Urea; D013006:Growth Hormone; D009584:Nitrogen